Elemer Piros
Stock Analyst at Rodman & Renshaw
(2.81)
# 1,885
Out of 4,681 analysts
107
Total ratings
43.42%
Success rate
7.96%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $2.08 | +428.85% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $22.01 | +127.17% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.43 | +1,088.81% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $22 | $0.65 | +3,310.85% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $3.45 | +3,005.95% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $0.40 | +3,400.00% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $7.28 | +820.33% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $43 | $4.38 | +881.74% | 1 | Jun 21, 2024 | |
| COYA Coya Therapeutics | Initiates: Buy | $18 | $6.35 | +183.46% | 7 | Jun 13, 2024 | |
| HOTH Hoth Therapeutics | Maintains: Buy | $12 → $7.5 | $0.82 | +814.63% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.69 | +787.57% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $8.14 | +158.14% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $4.49 | +746.33% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $2.97 | +1,246.80% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.74 | +579.26% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $10.00 | +1,040.00% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $4.10 | +4,778.05% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.71 | +519.33% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $8.68 | +280.18% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $35.42 | +12.93% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $40 | $1.23 | +3,152.03% | 3 | Jan 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.50 | +2,366.67% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $5.34 | +499.25% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $18.64 | +313.09% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.92 | +7,508.70% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $17.84 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $26.34 | +89.83% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $4.82 | +584.65% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $13.04 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $11.95 | +117.57% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $194.91 | -85.63% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $6.34 | +13,306.94% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $9.77 | +114.94% | 2 | Jul 12, 2017 |
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $2.08
Upside: +428.85%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $22.01
Upside: +127.17%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.43
Upside: +1,088.81%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $22
Current: $0.65
Upside: +3,310.85%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $3.45
Upside: +3,005.95%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $0.40
Upside: +3,400.00%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $7.28
Upside: +820.33%
Alto Neuroscience
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $4.38
Upside: +881.74%
Coya Therapeutics
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.35
Upside: +183.46%
Hoth Therapeutics
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $0.82
Upside: +814.63%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $1.69
Upside: +787.57%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $8.14
Upside: +158.14%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $4.49
Upside: +746.33%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $2.97
Upside: +1,246.80%
Jun 30, 2023
Reiterates: Buy
Price Target: $5
Current: $0.74
Upside: +579.26%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $10.00
Upside: +1,040.00%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $4.10
Upside: +4,778.05%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.71
Upside: +519.33%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $8.68
Upside: +280.18%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $35.42
Upside: +12.93%
Jan 4, 2022
Upgrades: Buy
Price Target: $40
Current: $1.23
Upside: +3,152.03%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.50
Upside: +2,366.67%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $5.34
Upside: +499.25%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $18.64
Upside: +313.09%
Oct 12, 2020
Initiates: Buy
Price Target: $70
Current: $0.92
Upside: +7,508.70%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $17.84
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $26.34
Upside: +89.83%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $4.82
Upside: +584.65%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $13.04
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $11.95
Upside: +117.57%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $194.91
Upside: -85.63%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $6.34
Upside: +13,306.94%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $9.77
Upside: +114.94%